Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Quinn

Showing results (61-70 of 255) with videos related to

Pageof 26
Sort By:
International Journal of Oncology|June 15, 2006
Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cellsC Plasencia, E Martínez-Balibrea, A Martinez-Cardús, et al.
American Journal of Clinical Oncology|May 14, 2020
Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma TrialsSarah E Wong, David I Quinn, Georg A Bjarnason, et al.
Theranostics|March 21, 2020
Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteriaErik M Velez, Bhushan Desai, Lingyun Ji, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 31, 2019
Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with <sup>18</sup>F-FDG PET/CTHossein Jadvar, Erik M Velez, Bhushan Desai, et al.
BJU International|March 30, 2005
Molecular prognostic factors in bladder cancerMaurizio Buscarini, Marcus L Quek, Parkash Gill, et al.
Molecular Cancer Therapeutics|February 22, 2012
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigmSumanta Kumar Pal, Stephen Williams, David Y Josephson, et al.
Molecular Cancer Therapeutics|July 16, 2005
Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell linesCarmen Plasencia, Raveendra Dayam, Qingcai Wang, et al.
Psychiatric Services (Washington, D.C.)|February 3, 2011
One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancerKathleen Ell, Bin Xie, Suad Kapetanovic, et al.
General Hospital Psychiatry|May 9, 2007
Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C studyKathleen Ell, Brenda Quon, David I Quinn, et al.
Expert Review of Anticancer Therapy|October 14, 2005
Postchemotherapy residual masses in advanced seminoma: current management and outcomesMarcus L Quek, Vannita Simma-Chiang, John P Stein, et al.
Pageof 26

Showing results (61-70 of 255) with videos related to

Sort By:
Pageof 26
International Journal of Oncology|June 15, 2006
Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cellsC Plasencia, E Martínez-Balibrea, A Martinez-Cardús, et al.
American Journal of Clinical Oncology|May 14, 2020
Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma TrialsSarah E Wong, David I Quinn, Georg A Bjarnason, et al.
Theranostics|March 21, 2020
Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteriaErik M Velez, Bhushan Desai, Lingyun Ji, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 31, 2019
Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with <sup>18</sup>F-FDG PET/CTHossein Jadvar, Erik M Velez, Bhushan Desai, et al.
BJU International|March 30, 2005
Molecular prognostic factors in bladder cancerMaurizio Buscarini, Marcus L Quek, Parkash Gill, et al.
Molecular Cancer Therapeutics|February 22, 2012
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigmSumanta Kumar Pal, Stephen Williams, David Y Josephson, et al.
Molecular Cancer Therapeutics|July 16, 2005
Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell linesCarmen Plasencia, Raveendra Dayam, Qingcai Wang, et al.
Psychiatric Services (Washington, D.C.)|February 3, 2011
One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancerKathleen Ell, Bin Xie, Suad Kapetanovic, et al.
General Hospital Psychiatry|May 9, 2007
Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C studyKathleen Ell, Brenda Quon, David I Quinn, et al.
Expert Review of Anticancer Therapy|October 14, 2005
Postchemotherapy residual masses in advanced seminoma: current management and outcomesMarcus L Quek, Vannita Simma-Chiang, John P Stein, et al.
Pageof 26